Overview

* Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline

* Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year

* Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count

Outlook

* Bruker ( BRKR ) expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoy

* Company forecasts FY2025 non-GAAP EPS of $1.85 to $1.90

* Bruker ( BRKR ) anticipates significant margin expansion and EPS growth in FY2026

Result Drivers

* BOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma markets

* PRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customers

* DEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $860.50 $848.72

Revenue mln mln (12

Analysts

)

Q3 Beat $0.45 $0.33

Adjusted (13

EPS Analysts

)

Q3 Net -$58.50

Income mln

Q3 Gross $379.40

Profit mln

Q3 $431.20

Operatin mln

g

Expenses

Q3 -$51.80

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)